Skip to main content

EVGN · Evogene Ltd. · Investor Relations

Track EVGN — free
$0.37 0.00 (-0.13%)
Market Cap
$5.85M
Shares
15.80M
Volume · Oct 22 4398 Avg daily vol (3M) 1.41M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-08-18 Q2 FY2026 Earnings conference call (announced in 6-K) Earnings call
2026-06-22 BIO International Convention 2026 Event
2026-05-20 Q1 FY2026 Earnings conference call (announced in 6-K) Earnings call
2026-05-19 24th Schrödinger European User Group Meeting Event
2026-03-23 BIO-Europe Spring 2026 Event
2026-03-05 Q4 Earnings conference call (announced in 6-K) Earnings call
2025-11-03 BIO-Europe 2025 Event
2025-09-09 Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York Conference
2025-06-16 BIO 2025 Boston Event
2025-05-25 AI x FoodTech Event
2025-05-20 Biomed Israel 2025 Event
2025-03-17 BioEurope Spring Event
2024-11-24 Evogene Earnings Call Q3 2024 21 11 2024 Earnings call
2024-11-04 Dr. Ruth Gross, Evogene’s VP of Business Development for Pharma, to attend BIO-Europe 2024 Event
2024-11-04 BIO-Europe 2024 Event
2024-10-20 HLTH 2024 Las Vegas, USA Event
2024-10-20 Dr. Ruth Gross, Evogene’s VP of Business Development for Pharma, to attend HLTH 2024 in Las Vegas Event
2024-09-01 Evogene Earnings Call Q2 2024 Earnings call
2024-07-24 BIO Asia-Taiwan 2024 Event
2024-06-06 2024 Annual General Meeting of Shareholders Shareholder meeting
2024-06-03 Dr. Ruth Gross, Evogene’s VP of Business Development for Pharma, to attend BIO International Convention 2024 Event
2024-06-03 BIO International Convention 2024 Event
2024-05-31 Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting Shareholder meeting
2024-05-23 Evogene First Quarter 2024 Financial Results, May 23, 2024 Results publication
2024-05-23 Evogene Earnings Call Q1 2024 Earnings call

Source: https://evogene.com/investor-relations/

Key facts CIK 1574565 CUSIP M4119S187 13F (30d) 1 filings 1 filers Visit website Investor relations